IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Tokio Marine Asset Management Co. Ltd.

Tokio Marine Asset Management Co. Ltd. decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 6,864 shares of the company’s stock after selling 164 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in IDEXX Laboratories were worth $3,810,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. International Assets Investment Management LLC increased its holdings in shares of IDEXX Laboratories by 51,631.3% during the 4th quarter. International Assets Investment Management LLC now owns 547,834 shares of the company’s stock worth $304,075,000 after buying an additional 546,775 shares during the last quarter. Winslow Capital Management LLC increased its holdings in shares of IDEXX Laboratories by 24.9% during the 3rd quarter. Winslow Capital Management LLC now owns 689,873 shares of the company’s stock worth $301,661,000 after buying an additional 137,621 shares during the last quarter. Barclays PLC increased its holdings in shares of IDEXX Laboratories by 46.7% during the 3rd quarter. Barclays PLC now owns 248,476 shares of the company’s stock worth $108,651,000 after buying an additional 79,102 shares during the last quarter. abrdn plc increased its holdings in shares of IDEXX Laboratories by 46.5% during the 4th quarter. abrdn plc now owns 246,130 shares of the company’s stock worth $136,614,000 after buying an additional 78,166 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in shares of IDEXX Laboratories by 51.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 225,150 shares of the company’s stock worth $98,353,000 after buying an additional 76,350 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Buying and Selling

In other news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the completion of the sale, the chief executive officer now owns 79,247 shares in the company, valued at approximately $45,377,624.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total value of $6,871,320.00. Following the completion of the transaction, the chief executive officer now owns 79,247 shares in the company, valued at approximately $45,377,624.67. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Brian P. Mckeon sold 23,326 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the completion of the transaction, the chief financial officer now owns 29,718 shares of the company’s stock, valued at approximately $16,939,557.18. The disclosure for this sale can be found here. Insiders sold a total of 43,524 shares of company stock worth $24,871,960 over the last 90 days. 2.18% of the stock is owned by insiders.

IDEXX Laboratories Stock Up 0.1 %

IDXX stock traded up $0.46 during midday trading on Wednesday, hitting $494.26. The company’s stock had a trading volume of 493,029 shares, compared to its average volume of 431,297. The firm has a market capitalization of $41.05 billion, a P/E ratio of 49.08, a PEG ratio of 3.69 and a beta of 1.26. The firm has a 50-day simple moving average of $533.74 and a 200-day simple moving average of $510.50. IDEXX Laboratories, Inc. has a 52-week low of $372.50 and a 52-week high of $583.39. The company has a quick ratio of 1.17, a current ratio of 1.57 and a debt-to-equity ratio of 0.42.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, beating analysts’ consensus estimates of $2.12 by $0.20. The company had revenue of $901.60 million for the quarter, compared to analysts’ expectations of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. IDEXX Laboratories’s quarterly revenue was up 8.8% on a year-over-year basis. During the same period last year, the firm earned $2.05 earnings per share. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.15 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on IDXX shares. JPMorgan Chase & Co. increased their price objective on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Barclays increased their price objective on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. Piper Sandler cut shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective for the company. in a research report on Tuesday, January 30th. Finally, The Goldman Sachs Group raised their price target on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $591.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.